Global B2B Pharmaceutical Sourcing · Dossier Licensing · Named-Patient Access
💬 WhatsApp · Sign in · Register
Poractant Alfa bulk supplier for pharma manufacturers

Poractant Alfa 80 mg/mL Suppliers & Bulk Manufacturers

Available Forms: Intratracheal suspension

Available Strengths: 80 mg/mL

Reference Brands: Curosurf(Eu & US)

Category: Respiratory Disorder

Poractant Alfa (Curosurf) is a natural surfactant used to treat Respiratory Distress Syndrome (RDS) in preterm infants. Available in the US and EU, it comes in 80 mg/mL strength (120 mg and 240 mg vials) and is trusted for effective neonatal respiratory care in NICUs worldwide.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

Product Description: Poractant Alfa, sold under the brand name Curosurf, is a natural surfactant used to treat Respiratory Distress Syndrome (RDS) in premature infants. Derived from porcine lung extract, it contains vital surfactant proteins (SP-B and SP-C) that help reduce surface tension in the lungs and improve oxygenation. Curosurf is administered via intratracheal suspension and is available in 80 mg/mL concentrations in 1.5 mL (120 mg) and 3 mL (240 mg) vials. Widely approved and marketed in both the US and EU, Curosurf is trusted in NICUs globally for its proven efficacy in neonatal respiratory support.

Poractant Alfa — third party manufacturing & bulk supply

Poractant Alfa 80 mg/mL is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.
Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.
Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Poractant Alfa is supplied as Intratracheal suspension — a dosage form priced by order value, so the indicative MOQ is a minimum order value of USD 5,000 per product. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Poractant Alfa listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Poractant Alfa →
Back to Listing

Frequently Asked Questions

Poractant Alfa is listed as Intratracheal suspension in 80 mg/mL. Further strengths and pack presentations are confirmed with the manufacturer at RFQ stage.

Poractant Alfa is referenced against Curosurf(Eu & US). Reference brands are shown for identification only and remain the property of their respective trademark owners.

Related Products

Acetylcysteine Oral Solution

Strength:
10% (100 mg/mL), 20% (200 mg/mL)

Form: Oral Solution

Reference Brands: Mucomyst(US); Fluimucil(EU)

View Details
Glycopyrrolate And Indacaterol

Strength:
27.5 mcg + 15.6 mcg or 85 mcg + 43 mcg

Form: Subcutaneous injection

Reference Brands: Utibron Neohaler(US), Ultibro Breezhaler(EU)

View Details
Acetylcysteine

Strength:
600 mg

Form: Effervescent Tablets

Reference Brands: Cetylev(US); NACSYS(EU)

View Details
Pirfenidone Tablet

Strength:
267 mg , 801 mg

Form: Tablet

Reference Brands: Esbriet(US & EU)

View Details
Poractant Alfa

Strength:
240 mg

Form: Injection

Reference Brands:

View Details
Dalteparin

Strength:
10000 IU

Form: Injection

Reference Brands: Fragmin (US/EU)

View Details
Dalteparin

Strength:
2500IU

Form: Injection

Reference Brands: Fragmin (US/EU)

View Details
Dalteparin

Strength:
5000IU

Form: Injection

Reference Brands: Fragmin (US/EU)

View Details
Enquire Now

Quick Response Guaranteed | Verified Suppliers

Subscribe to Our Newsletter

Stay updated on pharma trends and sourcing opportunities.

Please enter the correct answer.
This website uses cookies to ensure you get the best experience. By using our site, you agree to our Privacy Policy.